{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:06:26Z","timestamp":1788926786932,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03348-w","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:07:39Z","timestamp":1784714859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A kinetically inert platinum antitumor agent overcomes mutant p53-driven chemoresistance via oxidative stress-mediated DNA damage"],"prefix":"10.1007","volume":"43","author":[{"given":"Sourav","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti S.","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreyashi","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar Ranjan","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Sakpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Mehrotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malay","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritha","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"5","key":"3348_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41418-022-00989-y","volume":"29","author":"MC Kennedy","year":"2022","unstructured":"Kennedy MC, Lowe SW. Mutant p53: it\u2019s not all one and the same. Cell Death Differ. 2022;29(5):983\u20137.","journal-title":"Cell Death Differ"},{"issue":"1","key":"3348_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8(1):92.","journal-title":"Signal Transduct Target Ther"},{"key":"3348_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.788331","volume":"9","author":"X Gao","year":"2021","unstructured":"Gao X, Zheng X, Zhang Y, Dong L, Sun L, Zhao N, et al. Deficient or R273H and R248W mutations of p53 promote chemoresistance to 5-FU via TCF21\/CD44 axis-mediated enhanced stemness in colorectal carcinoma. Front Cell Dev Biol. 2021;9:788331.","journal-title":"Front Cell Dev Biol"},{"issue":"39","key":"3348_CR4","doi-asserted-by":"publisher","first-page":"41692","DOI":"10.18632\/oncotarget.6150","volume":"6","author":"MC Tung","year":"2015","unstructured":"Tung MC, Lin PL, Wang YC, He TY, Lee MC, Yeh SD, et al. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. Oncotarget. 2015;6(39):41692\u2013705.","journal-title":"Oncotarget"},{"issue":"24","key":"3348_CR5","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1080\/15384101.2019.1688951","volume":"18","author":"Y Huang","year":"2019","unstructured":"Huang Y, Liu N, Liu J, Liu Y, Zhang C, Long S, et al. Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA. Cell Cycle. 2019;18(24):3442\u201355.","journal-title":"Cell Cycle"},{"issue":"7","key":"3348_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.191","volume":"6","author":"BS Tan","year":"2015","unstructured":"Tan BS, Tiong KH, Choo HL, Chung FF, Hii LW, Tan SH, et al. Mutant p53\u2013R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis. 2015;6(7):e1826.","journal-title":"Cell Death Dis"},{"key":"3348_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24097917","author":"V Gandin","year":"2023","unstructured":"Gandin V, Hoeschele JD, Margiotta N. Special issue \u201cCisplatin in cancer therapy: molecular mechanisms of action 3.0.\u201d Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24097917.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3348_CR8","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022;12(5):2115\u201332.","journal-title":"Theranostics"},{"issue":"1","key":"3348_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41420-021-00554-5","volume":"7","author":"EV Sazonova","year":"2021","unstructured":"Sazonova EV, Kopeina GS, Imyanitov EN, Zhivotovsky B. Platinum drugs and taxanes: can we overcome resistance? Cell Death Discov. 2021;7(1):155.","journal-title":"Cell Death Discov"},{"issue":"5","key":"3348_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1039\/c3mt20252f","volume":"5","author":"K Suntharalingam","year":"2013","unstructured":"Suntharalingam K, Mendoza O, Duarte AA, Mann DJ, Vilar R. A platinum complex that binds non-covalently to DNA and induces cell death via a different mechanism than cisplatin. Metallomics. 2013;5(5):514\u201323.","journal-title":"Metallomics"},{"issue":"38","key":"3348_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202303958","volume":"62","author":"TR Panda","year":"2023","unstructured":"Panda TR, M M, Vaidya SP, Chhatar S, Sinha S, Mehrotra M, et al. The power of kinetic inertness in improving platinum anticancer therapy by circumventing resistance and ameliorating nephrotoxicity. Angew Chem Int Ed Engl. 2023;62(38):e202303958.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"3348_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05408-1","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13(11):974.","journal-title":"Cell Death Dis"},{"issue":"17","key":"3348_CR13","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1093\/nar\/gkn550","volume":"36","author":"A Kinner","year":"2008","unstructured":"Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008;36(17):5678\u201394.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"3348_CR14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","volume":"20","author":"R Scully","year":"2019","unstructured":"Scully R, Panday A, Elango R, Willis NA. DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol. 2019;20(11):698\u2013714.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3348_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-biochem-080320-110356","volume":"90","author":"BM Stinson","year":"2021","unstructured":"Stinson BM, Loparo JJ. Repair of DNA double-strand breaks by the nonhomologous end joining pathway. Annu Rev Biochem. 2021;90:137\u201364.","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"3348_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","volume":"4","author":"ZN Lei","year":"2020","unstructured":"Lei ZN, Tian Q, Teng QX, Wurpel JND, Zeng L, Pan Y, et al. Understanding and targeting resistance mechanisms in cancer. MedComm (Beijing). 2020;4(3):e265.","journal-title":"MedComm (Beijing)"},{"key":"3348_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100671","volume":"49","author":"X Cao","year":"2020","unstructured":"Cao X, Hou J, An Q, Assaraf YG, Wang X. Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat. 2020;49:100671.","journal-title":"Drug Resist Updat"},{"issue":"10","key":"3348_CR18","first-page":"2984","volume":"7","author":"A Reles","year":"2001","unstructured":"Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001;7(10):2984\u201397.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3348_CR19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3892\/ijo.2014.2747","volume":"46","author":"P Brachova","year":"2015","unstructured":"Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, et al. TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol. 2015;46(2):607\u201318.","journal-title":"Int J Oncol"},{"key":"3348_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052232","author":"C Madeddu","year":"2025","unstructured":"Madeddu C, Lai E, Neri M, Sanna E, Gramignano G, Nemolato S, et al. Association between TP53 mutations and platinum resistance in a cohort of high-grade serous ovarian cancer patients: novel implications for personalized therapeutics. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26052232.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3348_CR21","doi-asserted-by":"publisher","first-page":"8921","DOI":"10.18632\/oncotarget.13475","volume":"8","author":"K Hientz","year":"2017","unstructured":"Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017;8(5):8921\u201346.","journal-title":"Oncotarget"},{"issue":"6","key":"3348_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00280-004-0767-4","volume":"53","author":"KT Chan","year":"2004","unstructured":"Chan KT, Lung ML. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol. 2004;53(6):519\u201326.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"30","key":"3348_CR23","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1038\/sj.onc.1205704","volume":"21","author":"EN Pugacheva","year":"2002","unstructured":"Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ, Chumakov PM. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene. 2002;21(30):4595\u2013600.","journal-title":"Oncogene"},{"issue":"3","key":"3348_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ijc.20818","volume":"114","author":"WP Tsang","year":"2005","unstructured":"Tsang WP, Ho FY, Fung KP, Kong SK, Kwok TT. p53\u2013R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005;114(3):331\u20136.","journal-title":"Int J Cancer"},{"issue":"3","key":"3348_CR25","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1158\/1535-7163.MCT-06-0336","volume":"6","author":"RP Wong","year":"2007","unstructured":"Wong RP, Tsang WP, Chau PY, Co NN, Tsang TY, Kwok TT. p53\u2013R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther. 2007;6(3):1054\u201361.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3348_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cllc.2022.08.007","volume":"24","author":"J Fu","year":"2023","unstructured":"Fu J, Tong Y, Xu Z, Li Y, Zhao Y, Wang T, et al. Impact of TP53 mutations on EGFR-tyrosine kinase inhibitor efficacy and potential treatment strategy. Clin Lung Cancer. 2023;24(1):29\u201339.","journal-title":"Clin Lung Cancer"},{"issue":"15","key":"3348_CR27","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.2174\/0929867323666161214114948","volume":"24","author":"SP Basourakos","year":"2017","unstructured":"Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC. Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions. Curr Med Chem. 2017;24(15):1586\u2013606.","journal-title":"Curr Med Chem"},{"issue":"suppl 1","key":"3348_CR28","doi-asserted-by":"publisher","first-page":"e478s","DOI":"10.6061\/clinics\/2018\/e478s","volume":"73","author":"CRR Rocha","year":"2018","unstructured":"Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB, Menck CFM. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo). 2018;73(suppl 1):e478s.","journal-title":"Clinics (Sao Paulo)"},{"issue":"8","key":"3348_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1101\/gad.1897010","volume":"24","author":"TG Oliver","year":"2010","unstructured":"Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010;24(8):837\u201352.","journal-title":"Genes Dev"},{"issue":"31","key":"3348_CR30","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1200\/JCO.2010.34.3616","volume":"29","author":"LE Wang","year":"2011","unstructured":"Wang LE, Yin M, Dong Q, Stewart DJ, Merriman KW, Amos CI, et al. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol. 2011;29(31):4121\u20138.","journal-title":"J Clin Oncol"},{"key":"3348_CR31","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026070","author":"AB Williams","year":"2016","unstructured":"Williams AB, Schumacher B. P53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med. 2016. https:\/\/doi.org\/10.1101\/cshperspect.a026070.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"3348_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/humu.22528","volume":"35","author":"J Li","year":"2014","unstructured":"Li J, Yang L, Gaur S, Zhang K, Wu X, Yuan YC, et al. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy. Hum Mutat. 2014;35(5):575\u201384.","journal-title":"Hum Mutat"},{"key":"3348_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217736","volume":"625","author":"H Luo","year":"2025","unstructured":"Luo H, Huang MF, Xu A, Wang D, Gingold JA, Tu J, et al. Mutant p53 confers chemoresistance by activating KMT5B-mediated DNA repair pathway in nasopharyngeal carcinoma. Cancer Lett. 2025;625:217736.","journal-title":"Cancer Lett"},{"issue":"4","key":"3348_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/nan.12584","volume":"46","author":"JL Yang","year":"2020","unstructured":"Yang JL, Chen WY, Mukda S, Yang YR, Sun SF, Chen SD. Oxidative DNA damage is concurrently repaired by base excision repair (BER) and apyrimidinic endonuclease 1 (APE1)-initiated nonhomologous end joining (NHEJ) in cortical neurons. Neuropathol Appl Neurobiol. 2020;46(4):375\u201390.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"3348_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.629266","volume":"11","author":"LY Li","year":"2020","unstructured":"Li LY, Guan YD, Chen XS, Yang JM, Cheng Y. DNA repair pathways in cancer therapy and resistance. Front Pharmacol. 2020;11:629266.","journal-title":"Front Pharmacol"},{"issue":"11","key":"3348_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2081-4","volume":"10","author":"M Kleih","year":"2019","unstructured":"Kleih M, B\u00f6pple K, Dong M, Gai\u00dfler A, Heine S, Olayioye MA, et al. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10(11):851.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3348_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0909-x","volume":"37","author":"H Yang","year":"2018","unstructured":"Yang H, Villani RM, Wang H, Simpson MJ, Roberts MS, Tang M, et al. The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res. 2018;37(1):266.","journal-title":"J Exp Clin Cancer Res"},{"key":"3348_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.101084","volume":"25","author":"US Srinivas","year":"2019","unstructured":"Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019;25:101084.","journal-title":"Redox Biol"},{"issue":"11","key":"3348_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081162","volume":"8","author":"R Marullo","year":"2013","unstructured":"Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS, et al. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS ONE. 2013;8(11):e81162.","journal-title":"PLoS ONE"},{"issue":"10","key":"3348_CR40","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1096\/fj.02-0752rev","volume":"17","author":"MS Cooke","year":"2003","unstructured":"Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17(10):1195\u2013214.","journal-title":"FASEB J"},{"issue":"18","key":"3348_CR41","doi-asserted-by":"publisher","first-page":"25377","DOI":"10.18632\/oncotarget.8298","volume":"7","author":"V Sharma","year":"2016","unstructured":"Sharma V, Collins LB, Chen TH, Herr N, Takeda S, Sun W, et al. Oxidative stress at low levels can induce clustered DNA lesions leading to NHEJ mediated mutations. Oncotarget. 2016;7(18):25377\u201390.","journal-title":"Oncotarget"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03348-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03348-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03348-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:20:24Z","timestamp":1788924024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03348-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3348"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03348-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read the manuscript and provided their consent for the submission.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PDX studies were approved by the Institutional Ethics Committee of ACTREC-TMC and are per the guidelines and regulations (Reference Number- IEC#900898).","order":3,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"232"}}